HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn more about how to treat patients with HER-2/neu
positive invasive breast cancer (IBC). HER-2/neu is a type of protein that is known to be
over-expressed in aggressive breast cancer.
The study drug for this trial is DC1 study vaccine which is a HER2-sensitized dendritic cell
(DC) study vaccine. This study vaccine is made from the participant's blood cells collected
from a procedure called leukapheresis. Dendritic cells are immune cells that can tell the
immune system to fight infection. In laboratory testing and from previous studies in
participants, these cells may also help the immune system attack tumors such as breast
cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute